Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5045178 | 0.85 | CYP2C9 (0.52) | CYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL5040717 | 0.85 | CYP2C9 (0.52) | CYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL5634281 | 0.78 | CYP3A4 (0.41) | CYP3A4CYP2C9ALDH1A1GAA | |
| SCHEMBL5839023 | 0.78 | CYP3A4 (0.35) | CYP3A4CYP2C9ADORA2BKDM4EALDH1A1 | |
| SCHEMBL5634862 | 0.77 | CYP3A4 (0.41) | CYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL4885373 | 0.77 | CYP3A4 (0.36) | CYP3A4CYP2C9 | |
| SCHEMBL5747928 | 0.66 | CYP3A4 (0.43) | CYP3A4CYP2C9 | |
| SCHEMBL1218640 | 0.66 | CYP3A4 (0.43) | CYP3A4CYP2C9 | |
| SCHEMBL6047154 | 0.66 | CDK4 (0.41) | CYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL1814134 | 0.66 | CYP3A4 (0.43) | CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141567-B2 | Polysubstituted imidazopyridines as gastric secretion inhibitors | ALTANA PHARMA AG (DE) | 2006-11-28 | — | — | US | disclosed |
| US-20060035892-A1 | Nitrosated imidazopyridines | ATLANTA PHARMA AG (DE) | 2006-02-16 | — | — | US | disclosed |
| US-6869949-B2 | Polysubstituted imidazopyridines as gastric secretion inhibitors | ALTANA PHARMA AG (DE) | 2005-03-22 | — | — | US | disclosed |
| EP-1504003-A1 | NITROSATED IMIDAZOPYRIDINES | ALTANA Pharma AG (DE) | 2005-02-09 | — | — | EP | disclosed |
| US-20040214852-A1 | Polysubstituted imidazopyridines | ALTANA PHARMA AG (DE) | 2004-10-28 | — | — | US | disclosed |
| US-20040106642-A1 | POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS | ALTANA PHARMA AG (DE) | 2004-06-03 | — | — | US | disclosed |
| WO-2003091253-A1 | NITROSATED IMIDAZOPYRIDINES | ALTANA PHARMA AG (DE) | 2003-11-06 | — | — | WO | disclosed |
| EP-1332143-A1 | POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS | ALTANA Pharma AG (DE) | 2003-08-06 | — | — | EP | disclosed |
| WO-2002034749-A1 | POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS | ALTANA PHARMA AG (DE) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106642-A1 | POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS | GIPR, SLC10A2, VIP | CYP3A4 117/4885CYP2C9 821/4885ADORA2B 2082/4885 |
| US-20060035892-A1 | Nitrosated imidazopyridines | NOS2, NOS1, NOS3 | CYP3A4 76/4885CYP2C9 208/4885ADORA2B 1819/4885 |
| US-20040214852-A1 | Polysubstituted imidazopyridines | GIPR, VIP, SLC10A2 | CYP3A4 38/4885CYP2C9 438/4885ADORA2B 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.